Should I buy or sell Talis Biomedical stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Talis Biomedical in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" TLIS shares. View TLIS analyst ratings or view top-rated stocks .

What is Talis Biomedical's stock price target for 2024?

1 Wall Street analysts have issued 12 month target prices for Talis Biomedical's shares. Their TLIS share price targets range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests that the stock has a possible downside of 37.3%. View analysts price targets for TLIS or view top-rated stocks among Wall Street analysts .

How have TLIS shares performed in 2023?

Talis Biomedical's stock was trading at $6.6855 at the start of the year. Since then, TLIS stock has increased by 19.2% and is now trading at $7.9697. View the best growth stocks for 2023 here .

When is Talis Biomedical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our TLIS earnings forecast .

How were Talis Biomedical's earnings last quarter?

Talis Biomedical Co. (NASDAQ:TLIS) posted its earnings results on Tuesday, November, 14th. The company reported ($8.62) EPS for the quarter. The company earned $0.14 million during the quarter. Talis Biomedical had a negative net margin of 3,436.98% and a negative trailing twelve-month return on equity of 72.82%.

When did Talis Biomedical's stock split?

Talis Biomedical's stock reverse split before market open on Thursday, July 6th 2023. The 1-15 reverse split was announced on Thursday, July 6th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Talis Biomedical IPO?

(TLIS) raised $150 million in an initial public offering on Friday, February 12th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Piper Sandler served as the underwriters for the IPO and BTIG was co-manager.

Who are Talis Biomedical's major shareholders?

Talis Biomedical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Citigroup Inc. (0.29%), Citigroup Inc. (0.29%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bros Advisors Lp Baker, John Roger Moody Jr, Kimberly J Popovits, Ramesh Ramakrishnan and Randal W Scott. View institutional ownership trends .

How do I buy shares of Talis Biomedical?

Shares of TLIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Talis Biomedical Stock Price, News & Analysis (NASDAQ:TLIS)

$7.97

-0.08 (-0.99%)

(As of 12/8/2023 ET)

Compare

Today's Range: $7.22
▼
$8.15
50-Day Range: $4.36
▼
$8.05
52-Week Range: $4.35
▼
$9.75

Volume: 3,523 shs
Average Volume: 31,827 shs
Market Capitalization: $14.50 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Talis Biomedical MarketRank™ Stock Analysis

Analyst Rating: Sell
1.00 Rating Score
Upside/Downside: 37.3% Downside
$5.00 Price Target
Short Interest: Healthy
1.02% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.05 out of 5 stars

Medical Sector

936th out of 954 stocks

Analytical Instruments Industry

19th out of 19 stocks

0.5

Analyst's Opinion

Consensus Rating
Talis Biomedical has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, Talis Biomedical has a forecasted downside of 37.3% from its current price of $7.97.
Amount of Analyst Coverage
Talis Biomedical has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.02% of the float of Talis Biomedical has been sold short.
Short Interest Ratio / Days to Cover
Talis Biomedical has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Talis Biomedical has recently decreased by 0.58%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Talis Biomedical does not currently pay a dividend.
Dividend Growth
Talis Biomedical does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TLIS.

N/A

News and Social Media Coverage

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Talis Biomedical insiders have not sold or bought any company stock.
Percentage Held by Insiders
46.00% of the stock of Talis Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Talis Biomedical is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Talis Biomedical is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Talis Biomedical has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Talis Biomedical Stock (NASDAQ:TLIS)

Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also develops Talis One tests for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B. The company was incorporated in 2013 and is headquartered in Redwood, California.

TLIS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TLIS Stock News Headlines

November 14, 2023 | bizjournals.com

Peninsula diagnostics company to close Redwood City labs and offices, pursue 'strategic alternatives'

November 14, 2023 | finanznachrichten.de

Talis Biomedical Corporation: Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash

December 9, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 14, 2023 | msn.com

LICY, BTAI and HROW among mid-day movers

November 14, 2023 | msn.com

Talis reviewing strategic alternatives, stock rallies 35%

November 14, 2023 | msn.com

Why Talis Biomedical (TLIS) Stock Is Exploding Higher

November 14, 2023 | finance.yahoo.com

Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash

August 16, 2023 | msn.com

BTIG Maintains Talis Biomedical (TLIS) Sell Recommendation

December 9, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

August 16, 2023 | markets.businessinsider.com

BTIG Maintains Sell Rating for Talis Biomedical: Here's What You Need To Know

August 11, 2023 | finance.yahoo.com

Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update

August 9, 2023 | benzinga.com

A Preview Of Talis Biomedical's Earnings

August 3, 2023 | finance.yahoo.com

Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023

August 2, 2023 | finance.yahoo.com

Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)

August 1, 2023 | uk.finance.yahoo.com

TLIS - Talis Biomedical Corporation

July 24, 2023 | finance.yahoo.com

Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement

July 5, 2023 | finance.yahoo.com

Talis Biomedical Announces 1-for-15 Reverse Stock Split

May 23, 2023 | finance.yahoo.com

Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors, Announces Former Genomic Health CEO Kim Popovits as Lead Independent Director

May 12, 2023 | finanznachrichten.de

Talis Biomedical Corporation: Talis Biomedical Announces Business Update and First Quarter 2023 Financial Results

May 11, 2023 | seekingalpha.com

Talis Biomedical reports Q1 results

May 11, 2023 | msn.com

Talis Biomedical: Q1 Earnings Insights

May 9, 2023 | benzinga.com

Talis Biomedical Corporation (TLIS) Investor News: Robbins LLP Reminds Investors it is Investigating TLIS on Behalf of Shareholders

May 6, 2023 | benzinga.com

Talis Biomedical Stock (NASDAQ:TLIS), Dividends

May 4, 2023 | finance.yahoo.com

Talis Biomedical to Provide Business Update and Financial Results on May 11, 2023

May 2, 2023 | benzinga.com

Talis Biomedical Corporation (TLIS) Stockholders: Robbins LLP is Investigating TLIS on Behalf of Shareholders

April 4, 2023 | markets.businessinsider.com

BTIG Remains a Sell on Talis Biomedical (TLIS)

April 1, 2023 | seekingalpha.com

TLIS Talis Biomedical Corporation

See More Headlines

Receive TLIS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Talis Biomedical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 12/09/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Analytical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TLIS
CUSIP: N/A
CIK: 1584751
Web: talis.bio
Phone: 650-433-3000
Fax: N/A
Employees: 102
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.00
High Stock Price Target: $5.00
Low Stock Price Target: $5.00
Potential Upside/Downside: -37.3%
Consensus Rating: Sell
Rating Score (0-4): 1.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($41.78)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-113,010,000.00
Net Margins: -3,436.98%
Pretax Margin: -3,436.98%
Return on Equity: -72.82%
Return on Assets: -56.68%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.60
Quick Ratio: 10.60

Sales & Book Value

Annual Sales: $368,000.00
Price / Sales: 39.44
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $70.95 per share
Price / Book: 0.11

Miscellaneous

Outstanding Shares: 1,821,000
Free Float: 983,000
Market Cap: $14.51 million
Optionable: Not Optionable
Beta: 1.68

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Robert Kelley MBA (Age 51)
CEO & Director
Comp: $1.05M
Dr. Rustem F. Ismagilov Ph.D. (Age 49)
Co-Founder & Director
Comp: $75.36k
Dr. Andrew A. Lukowiak Ph.D. (Age 51)
President & Chief Scientific Officer
Mr. Liang Li Ph.D.
Co-Founder and Director of Technology & Strategy
Ms. Rebecca Markovich (Age 50)
Interim Chief Financial Officer
Ms. Emily Faucette
Senior Vice President of Corporate Communications & Investor Relations
Ms. Jill Green
Senior Vice President of Legal
Mr. Matthew Pepe
Vice President of Human Resource
Ms. Margaret Barrett M.S.
Controller
Gillian Green
Company Secretary

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

TLIS Stock Analysis - Frequently Asked Questions

Should I buy or sell Talis Biomedical stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Talis Biomedical in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" TLIS shares.
View TLIS analyst ratings or view top-rated stocks.
What is Talis Biomedical's stock price target for 2024?: 1 Wall Street analysts have issued 12 month target prices for Talis Biomedical's shares. Their TLIS share price targets range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests that the stock has a possible downside of 37.3%.
View analysts price targets for TLIS or view top-rated stocks among Wall Street analysts.
How have TLIS shares performed in 2023?: Talis Biomedical's stock was trading at $6.6855 at the start of the year. Since then, TLIS stock has increased by 19.2% and is now trading at $7.9697.
View the best growth stocks for 2023 here.
When is Talis Biomedical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our TLIS earnings forecast.
How were Talis Biomedical's earnings last quarter?: Talis Biomedical Co. (NASDAQ:TLIS) posted its earnings results on Tuesday, November, 14th. The company reported ($8.62) EPS for the quarter. The company earned $0.14 million during the quarter. Talis Biomedical had a negative net margin of 3,436.98% and a negative trailing twelve-month return on equity of 72.82%.

When did Talis Biomedical's stock split?: Talis Biomedical's stock reverse split before market open on Thursday, July 6th 2023. The 1-15 reverse split was announced on Thursday, July 6th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
When did Talis Biomedical IPO?: (TLIS) raised $150 million in an initial public offering on Friday, February 12th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Piper Sandler served as the underwriters for the IPO and BTIG was co-manager.
Who are Talis Biomedical's major shareholders?: Talis Biomedical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Citigroup Inc. (0.29%), Citigroup Inc. (0.29%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bros Advisors Lp Baker, John Roger Moody Jr, Kimberly J Popovits, Ramesh Ramakrishnan and Randal W Scott.
View institutional ownership trends.
How do I buy shares of Talis Biomedical?: Shares of TLIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TLIS) was last updated on 12/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Talis Biomedical Stock Price, News & Analysis (NASDAQ:TLIS)

Talis Biomedical MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Company Ownership

Earnings and Valuation

About Talis Biomedical Stock (NASDAQ:TLIS)

TLIS Stock Price History

TLIS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

TLIS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™